Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

NCT01878188 is registered in ClinicalTrials.gov with Anchiano Therapeutics Israel Ltd. as lead sponsor.

NCT NCT01878188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01878188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2013
Completion date
October 31, 2017
Enrollment
38 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

transitional cell carcinoma of bladder